Boston Scientific Corporation Q3 2026 Earnings Call Summary
Boston Scientific reported Q3 2026 earnings impacted by a cyber incident, reducing sales growth and EPS. The company faces challenges in EP and WATCHMAN franchises, China pricing, and supply constraints. Management expects 2027 to be a trough year, with recovery in 2028 driven by new product launches. A $500M restructuring program is planned to offset margin pressures. The Penumbra acquisition is delayed to early 2027. Pipeline delays affect FARAWAVE Ultra and FARAFLEX platforms.
How this was made
The 30-second read
Why it matters
The disclosed operational setbacks and guidance reductions are likely to weigh on the stock in the near term, while the announced restructuring offers a path to margin recovery.
Market read
Large‑cap med‑tech earnings with material operational and strategic updates; immediate relevance for traders with exposure to BSX.
What to watch
Potential upside from the upcoming Penumbra acquisition and new product launches slated for 2028.
Background
Boston Scientific provided its Q3 2026 earnings call summary, highlighting a cyber‑security incident, a $80 M GAAP charge, and a delayed Penumbra acquisition.
Ticker impact
Q3 2026 earnings call disclosed a cyber‑security outage, $0.07 EPS hit and a $150 M revenue headwind, plus a delayed Penumbra acquisition and $500 M restructuring plan.
likely downside as market prices in lower guidance and cyber‑incident costs
The disclosed EPS reduction, revenue hit and delayed acquisition are material new facts for a large‑cap medical device maker, prompting immediate re‑rating.
Market effects
Medical device sector may see broader concerns over cyber‑risk and supply‑chain resilience.
U.S. healthcare stocks could face short‑term pressure.
Limited to investors in med‑tech and related supply chains.
Counterpoint
The restructuring and long‑term growth pipeline could position BSX for a rebound once the cyber issue resolves.
Key entities
- companyBoston Scientific
Medical device manufacturer reporting Q3 2026 results.
- companyPenumbra
Target of a pending acquisition expected to close early 2027.
